Genmab — Februar 2016
-
he new therapy's potential lies in its unique mechanism of action. Darzalex is a first-in-class antibody that initiates an immune response after binding to CD38, a protein found on the surface of multiple myeloma cells. This approach has led to impressive response rates in heavily pre-treated patients. Although not measured head to head, it also appears far more tolerable than its contenders.
-
3 Potential Blockbusters Moving the Needle for Big Pharma in 2016 | The Motley Fool
These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.
The Motley Fool (www.fool.com)
-
tak for links helge. ser rigtig godt ud
-
nohope - jeg tvivler på, at Rachel vil svare på det spørgsmål på denne side af Q4. Det er nok snarere noget vi skal gemme til Q&A med Jan, så vi kan få en forståelse af de her leading indicators på toplinien
-
specifikke spørgsmål kommer nemt til at ligge meget tæt på kurspåvirkende informationer, mens generel forståelse for f.eks. prescriptions kan give os en del mere
-
Nordea: Genmab. Buying opportunity in spite of cautious guidance. We forecast USD 300M Darzalex sales in 2016 and 1 Billion in 2017. Genmab to be more cautious. Trim target to 1080 from 1100.
-
Nordea expect strong pipeline news throughout 2016
-
godt at se at Novod holder fast - mon ikke det er en usddkk adjustment?
-
Formodentlig
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind